Foghorn Therapeutics
G-Yoon Jamie Im is an accomplished chemist with extensive experience in medicinal chemistry, currently serving as Director of Medicinal Chemistry at Foghorn Therapeutics Inc. since 2024. Prior roles include Director of Medicinal Chemistry at Kestrel Therapeutics and Casma Therapeutics, as well as Associate Director at HotSpot Therapeutics, Inc. G-Yoon Jamie Im began a career in research at Ironwood Pharmaceuticals as a Principal Investigator and worked as a Postdoctoral Researcher at UCLA under the guidance of Professor Neil K. Garg. Educational credentials include a Ph.D. in Organic Chemistry from UCLA and a B.S. with special attainments in Chemistry and Mathematics from Washington and Lee University.
Foghorn Therapeutics
1 followers
Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Their proprietary Gene Traffic Control platform gives them an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing them to identify, validate, and potential drug targets within the system.